These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17181445)

  • 1. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
    Osman KA; Osman MM; Ahmed MH
    Expert Opin Drug Saf; 2007 Jan; 6(1):1-4. PubMed ID: 17181445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
    Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
    Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
    Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug-induced Nonalcoholic Steatohepatitis].
    Miyamura M; Yokota J; Saibara T
    Yakugaku Zasshi; 2016; 136(4):579-82. PubMed ID: 27040342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
    Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate.
    Ogawa Y; Murata Y; Saibara T; Nishioka A; Kariya S; Yoshida S
    Oncol Rep; 2003; 10(5):1473-8. PubMed ID: 12883726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
    Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer.
    Saphner T; Triest-Robertson S; Li H; Holzman P
    Cancer; 2009 Jul; 115(14):3189-95. PubMed ID: 19484789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
    Ahmed MH; Osman KA
    Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
    [No Abstract]   [Full Text] [Related]  

  • 15. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen-induced steatohepatitis.
    Pratt DS; Knox TA; Erban J
    Ann Intern Med; 1995 Aug; 123(3):236. PubMed ID: 7598311
    [No Abstract]   [Full Text] [Related]  

  • 17. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 18. Fatty liver and drugs.
    Grieco A; Forgione A; Miele L; Vero V; Greco AV; Gasbarrini A; Gasbarrini G
    Eur Rev Med Pharmacol Sci; 2005; 9(5):261-3. PubMed ID: 16237810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
    Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
    Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
    Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.